Physician profile
Andrew Gowdey
NPI 1083025951
$5,447.67
in general payments reported to CMS, 2019-2025
31 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,218 · 2020: $727 · 2021: $309 · 2022: $502 · 2023: $230 · 2024: $471 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,031.45 | 2019-2020 | |
| Boston Scientific Corporation | $937.30 | 2019-2023 | Spaceoar Vue System - 10ml |
| Coloplast Corp | $593.28 | 2020-2025 | |
| Janssen Biotech, INC. | $438.86 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $248.19 | 2019-2025 | Xtandi, Myrbetriq |
| Myriad Genetic Laboratories, INC. | $234.50 | 2021-2024 | Prolaris |
| Procept Biorobotics Corporation | $193.55 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Endo Pharmaceuticals INC. | $177.21 | 2019-2022 | |
| Allergan, INC. | $167.74 | 2019-2021 | |
| Urovant Sciences INC | $165.70 | 2021-2022 | |
| Pfizer INC. | $132.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $129.96 | 2023-2024 | Gemtesa, Orgovyx |
| Pharmaand Gmbh | $120.25 | 2025 | Rubraca |
| Tolmar, INC. | $120.25 | 2025 | Rubraca, Eligard |
| Teleflex LLC | $113.61 | 2022-2025 | Barrigel, Urolift |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $109.92 | 2019-2025 | Lynparza |
| Abbvie INC. | $101.75 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.39 | 2019-2025 | |
| Rochester Medical Corporation | $47.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.04 | 2025 | |
| Cook Medical LLC | $40.56 | 2024 | Litho 150 |
| Kowa Pharmaceuticals America, INC. | $40.19 | 2022 | |
| Ferring Pharmaceuticals INC. | $34.30 | 2024-2025 | Adstiladrin |
| Ambu INC. | $26.36 | 2025 | |
| Olympus America INC. | $24.56 | 2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $17.39 | 2025 | Provenge |
| Smith+Nephew, INC. | $16.35 | 2024 | Pico 7 |
| Caris Mpi, INC. | $15.10 | 2025 | Mi Cancer Seek |
| Axonics, INC. | $15.05 | 2023 | Bulkamid |
| Photocure INC | $13.53 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$158,840.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gowdey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.